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South Africa (SA) may be able to provide antiretroviral therapy 
(ART) to several million more people with HIV by 2019, using 
the current drug budget. While planned simplification of HIV 
service delivery promises to reduce expenditure, the drug cost 
of ART provision consumes the bulk of most HIV programme 
budgets, and is unlikely to decrease significantly, as multiple 
generic competitors have realised manufacturing efficiencies for 
current formulations. SA has the largest ART programme in the 
world, with domestic funding accounting for >75% of all HIV 
spending.[1] For the year 2014 - 2105, USD350 million was spent 
on ART for just <3 million people living with HIV, most of it on 
first-line treatment.[2-4] From mid-2016, the number of people on 
ART has increased to 3.4 million, ~145  000 of them on second-
line treatment and >700 on third-line treatment. An increase in 
public spending is expected to continue, owing in part to recent 
changes in ART initiation guidelines. The national Department of 
Health (DoH) announced its endorsement to ‘treat all’ approaches 
from September 2016, dropping CD4 thresholds for ART initiation 
completely, theoretically doubling the number eligible for ART to 
>6 million people.[4] This change and the steady improvement in 
life expectancy of patients on ART mean that the ART budget must 
accommodate millions of people for several decades of life.[5,6]
With >300  000 people initiating therapy annually (a number that 
will almost double, according to the DoH) on the efavirenz/teno-
fovir disoproxil fumarate/emtricitabine/ (EFV/TDF/FTC) fixed-dose 
generic (FTC and lamivudine (3TC) are interchangeable in terms 
of efficacy and cost, with 3TC used more in the private sector and 
outside SA[5]), SA is the largest consumer of generic ART in the 
world, using a quarter of global production. Two drugs, dolutegravir 
(DTG) and a new prodrug variant of tenofovir, tenofovir alafenamide 
(TAF), have been or are currently in the process of being licensed to 
multiple generic manufacturers by originator manufacturers directly 
or through voluntary licensing via Medicine Patent Pool (United 
Nations, Switzerland) processes. In short, replacing EFV, which is 
very vulnerable to resistance and drives most first-line side-effects, 
with DTG provides a better tolerated and cheaper drug with a high 
resistance barrier, limiting transition to expensive and less well-
tolerated, toxic next-line treatments. TAF is substantially cheaper 
than TDF, a major cost driver of first-line therapy, and provides 
some bone and renal toxicity benefits.[5,7] Co-formulating the two 
drugs with FTC or 3TC would also substantially reduce the size of 
the current tablet, making it easier to manufacture, while saving on 
packaging and storage space. However, the two drugs – TAF and DTG 
– are manufactured by competing companies, where commercial 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
CLINICAL UPDATE
Cutting the cost of South African antiretroviral therapy 
using newer, safer drugs
W D F Venter,1 FCP (SA), MMed; B Kaiser,2 MPH, PharmD, BCPS; Y Pillay,3 PhD; F Conradie,4 MB BCh; G B Gomez,5 PhD; P Clayden;6 
M Matsolo;7 C Amole,8 BA; L Rutter,7 BA; F Abdullah,9 MB ChB, FCPHM, BSc Hons (Epi); E J Abrams,10 MD; C P Casas,11 MSc; 
M Barnhart,12 MD, MPH; A Pillay,13 PhD; A Pozniak,14 MD, FRCP; A Hill,14 PhD; L Fairlie,1 FCPaed (SA); M Boffito,14 MD, PhD; 
M Moorhouse,1 MB BCh; M Chersich,1 MB BCh, PhD; C Serenata,1 MBA; J Quevedo,8 BS; G Loots15
1 Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa
2 Formerly UNITAID, Geneva, Switzerland
3  HIV/AIDS, TB and Maternal, Child and Women’s Health in the South African National Department of Health, Pretoria, South Africa
4  Clinical HIV Research Unit, University of the Witwatersrand and Southern African HIV Clinicians Society, Johannesburg, South Africa
5  Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center, Amsterdam, The Netherlands
6 HIV i-Base, London, UK
7 Treatment Action Campaign, Cape Town, South Africa
8 Clinton Health Access Initiative, New York, USA
9 South African National AIDS Council, Pretoria, South Africa 
10  International Center for AIDS Care and Treatment Programs (ICAP), Mailman School of Public Health and College of Physicians and Surgeons, 
Columbia University, New York, USA
11 UNITAID, Geneva, Switzerland
12 USAID Bureau for Global Health, Washington, DC, USA
13  Health Regulation and Compliance, South African National Department of Health, Pretoria, South Africa
14  Chelsea and Westminster Hospital and St Stephens AIDS Trust, London, UK
15  South African Department of Science and Technology, Pretoria, South Africa
Corresponding author: W D F Venter (fventer@wrhi.ac.za)
Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, 
but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have 
access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, 
and demonstrate the large cost savings to the South African HIV programme if these are successful.
S Afr Med J 2017;107(1):28-30. DOI:10.7196/SAMJ.2017.v107i1.12058
29       January 2017, Vol. 107, No. 1
IN PRACTICE
interests in high-income countries compel them to develop other 
co-formulations, which are of substantially higher cost or have signi-
ficant questions regarding their use in patients with tuberculosis 
(TB) or in pregnancy. Botswana is planning a move to a DTG-based 
regimen for first line, based on the impressive performance of this 
regimen in high-income countries, but in the absence of data on TB 
and pregnancy.
A large, independent, randomised controlled study (ADVANCE) 
(Table 1), will address the substantial burden of evidence needed 
to change guidelines, with the hope that this study will provide 
evidence for initiating and switching millions of people on ART to 
the new regimen (to date, the combination DTG/TAF/FTC has not 
been specifically tested in clinical trials). Results from ADVANCE 
may be available by the end of 2018 for Medicines Control Council 
(MCC) registration and DoH guidelines and tender processes, so 
that the new regimen can be rolled out from 2019. The ADVANCE 
study has been designed by a unique multidisciplinary group 
of researchers, clinicians, activists, donors, and public health 
specialists, with substantial input and support from agencies, such 
as the World Health Organization (WHO) and the national DoH, 
as well as both originator and generic manufacturers. Aligned 
studies will address certain issues, such as the use of the new 
drugs in patients receiving rifampicin-containing TB regimens, 
and among pregnant women and adolescents, while partners are 
further working on new technologies, including nanotechnologies, 
to reduce the price of second-line drugs.
The introduction in SA of this new regimen has the potential to 
substantially reduce the cost of first-line ART, while also being safer 
and better tolerated, therefore limiting the need for second-line ART. 
We estimate potential cost savings for SA if the studies demonstrate 
efficacy and safety, and justify the urgency in completing the study 
swiftly and transitioning to the new combination without delay.
Cost and other assumptions in the 
model
Cost savings of introducing the new regimen can be expected from:
• Lower drug costs of DTG/TAF-containing regimens compared 
with current first-line drugs. The cost of current first-line 
therapy is ~USD110/patient/year.[3,6] We have estimated an initial 
20% saving (a conservative estimate provided to the authors by 
manufacturers for DTG/TAF cost saving over the current regimen 
of EFV/TDF/FTC) and a 50% saving once volumes are met (as 
estimated by the Clinton Health Access Initiative (CHAI), USA). 
• Limiting transition of patients from first- to second-line therapy 
owing to better tolerability and robustness of DTG/TAF-containing 
regimens. These savings are expected to accumulate through lower 
second-line drug costs (second-line therapy costs ~USD350[5,8]), but 
also lower service delivery costs and decreased viral load monitoring. 
The rate of transition from first-line to second-line regimens is not 
available. Since 2004, the number of SA patients on second-line 
treatment have increased to 145 000. These figures may have been 
initially inflated owing to the use of more toxic stavudine-containing 
regimens in use until 2010. In the calculations, we assume a 2% 
annual transition from first- to second-line treat ment for anyone on 
the EFV-containing regimen (DoH assumed 4% for the previous ten-
der, but the limited data suggest that this is an underestimation). In 
comparison, as no DTG-related virological failure due to resistance 
has occurred in the initial 600 000 patients on first-line treatment in 
Europe or the USA, we assumed that there would be no significant 
switching to second-line therapy in the years modelled.[9] For simplic-
ity, and because the numbers are small, we have not factored in the 
effect on third-line initiations.
A move to DTG-TAF-based regimens will have to be phased as 
manufacturers scale-up and patients (both new initiations and estab-
lished patients) transition to the new regimen. In this analysis, we 
compare three transition scenarios of different scale-up assumptions 
with the current status quo: 
• Status quo: EFV/TDF/FTC remains the first-line regimen, with 
300  000 people initiating first-line treatment annually and 2% 
migrating to second-line treatment.
• Conservative scenario: continued initiation at 300 000 annually – 
at first only new initiations qualifying for DTG/TAF/FTC, others 
remaining on EFV/TDF/FTC and slowly transitioning to the new 
regimen over 3 years.
• Moderate scenario: initiations at 400 000 annually, with at first only 
new initiations qualifying for DTG/TAF/FTC, and transitioning 
over 2 years.
• Aggressive scenario: initiations at 500 000 annually, with everyone 
moving to DTG/TAF/FTC within a year.
Calculations are for expected savings in drug costs for 4 years from 
2019; USD values are used, as manufacturing is largely dependent on 
USD-based acquisitions of materials. The USD450 million baseline is 
the estimated cost of ART in 2019, based on the current costs for 
2014 - 2015 and the estimated programme growth. We note that there 
are currently wide currency fluctuations, introducing manufacturing 
and other uncertainties. Future costs have not been discounted, 
nor lost-to-follow-up costs or decreased costs associated with less 
second-line monitoring; we have also not factored in costs of the 
introduction of new regimens, such as training. 
Results
As shown in Figs 1 and 2, all scenarios for the introduction of 
DTG/TAF-based regimens translate into substantial reductions 
in ART drug costs for SA. The aggressive model with new drugs 
treats 800 000 people more than the status quo over 4 years, and 
with >USD200 million saving. Moreover, using the current budget 
for ART drugs, we could cover the ART drug costs of treating an 
additional 2 million people.
Table 1. Summary of the ADVANCE study
Investigator driven, study drug donated by company
Funded by USAID and UNITAID
Conducted in Johannesburg, start date: beginning 2017
Non-inferiority design, ~1 100 participants, over 96 weeks
Eligibility criteria
Needing first-line ART
 No TB treatment, not pregnant (addressed in other studies; those 
contracting TB or falling pregnant may continue in the study)
No CD4 threshold
>12 years of age, >40 kg
Compares three combinations: DTG/TAF v. DTG/TDF v. EFV/
TDF (current first line in SA), all with FTC
Primary endpoint is viral suppression at 48 weeks
Pharmacokinetic sampling of both DTG/TAF in those who 
contract TB or become pregnant
USAID = United States Agency for International Development. 
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Conclusion
The introduction of DTG/TAF-based regimens could potentially 
translate into substantial savings to the SA health budget, if ADVANCE 
is completed rapidly and is successful, and if manufacturing is quickly 
scaled up to meet demand. Essentially, with the current ART budget, 
we could purchase DTG/TAF/FTC for everyone taking ART at the 
end of 4 years, even assuming the high end of 500 000 new patients 
needing treatment annually.
Clinical evidence of the efficacy of both drugs is compelling, 
although questions remain around drug interactions with rifampicin 
and use in pregnancy, all being evaluated in clinical trials. In tandem, 
addressing the complex registration of new drugs (TAF has yet to 
be registered by the MCC) and combinations, including those of 
generic manufacturers, will need synchronisation, currently being 
co-ordinated locally by CHAI, in partnership with the DoH. If TAF 
is not registered in time, or if problems arise in the TB or pregnancy 
studies, the DTG/TAF/FTC regimen also being tested in ADVANCE 
confers significant clinical and cost benefits. Finally, ART drug costs 
account for about a quarter of cost of HIV care in SA (it is a greater 
proportion in countries where salaries are lower and laboratory 
monitoring is more limited); therefore, attention to systemic cost 
drivers are still needed.[7,10]
If successful, patients will benefit with a much safer and more 
forgiving regimen in a smaller tablet, government and other funders 
will save money, while pharmaceutical producers will have simplified 
manufacturing, using lower volumes of active pharmaceutical ingre-
dients. In an age of escalating medical costs, we are seldom presented 
with a win-win scenario with regard to clinical care. The clinical stud-
ies and registration processes to secure inclusion of these two new 
drugs, if successful, would be a huge SA victory to complement the 
current successful ART roll-out, with knock-on effects for the entire 
region and other low- and middle-income countries.
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Fig. 1. Estimated increase in patients needing ART in SA. Number of people 
on antiretrovirals in SA (status quo = 300 000 initiating therapy annually, 
2% migration to second line; conservative = 300 000 annually, transition 
from old regimen (EFV/TDF/FTC) to new (DTG/TAF/FTC) over 3 years; 
moderate = new regimen, 400 000 annually, transition over 2 years; aggres-


















Years (assuming implementation in 2019 - 2020)




Fig. 2. Estimated crude savings on antiretroviral drugs (assuming implemen-
tation of new regimen in 2019 - 2020). Cumulative savings compared with 
status quo (conservative = 300 000 annually, transition from old regimen to 
new over 3 years; moderate = new regimen, 400 000 annually, transition over 
2 years; aggressive = new regimen, 500 000 annually, transition over 1 year).
